Cargando…

Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458818/ https://www.ncbi.nlm.nih.gov/pubmed/31000930 http://dx.doi.org/10.4103/0970-1591.257220

Ejemplares similares

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
por: Sharma, Aditya Prakash
Publicado: (2017)

Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
por: Koroki, Yosuke, et al.
Publicado: (2022)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Erratum to “Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients"
por: Owlia, Mohammad Bagher, et al.
Publicado: (2012)

Erratum to: Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
por: Jiménez-Fonseca, P., et al.
Publicado: (2014)

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2021)

Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
por: Kvorning Ternov, Klara, et al.
Publicado: (2019)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
por: El-Amm, Joelle, et al.
Publicado: (2013)

Erratum to: Prednisolone and acupuncture in Bell’s palsy: study protocol for a randomized, controlled trial
por: Xia, Feng, et al.
Publicado: (2014)

Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real‐world data (ACES)
por: Das, Prantik, et al.
Publicado: (2020)

Erratum to: Adaptive Introgression Facilitates Adaptation to High Latitudes in European Aspen (Populus Tremula L.)
por: Rendón-Anaya, Martha, et al.
Publicado: (2022)

Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
por: Koroki, Yosuke, et al.
Publicado: (2021)

Effects of oral N-acetylcysteine combined with oral prednisolone on idiopathic sudden sensorineural hearing loss: Erratum
Publicado: (2022)

Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2016)

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
por: Massard, C., et al.
Publicado: (2017)

Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer
por: Goyal, Jatinder, et al.
Publicado: (2013)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
por: Tolcher, A. W., et al.
Publicado: (2012)

STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
por: Sharma, Aditya Prakash, et al.
Publicado: (2018)

Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets
por: Patel, Amol, et al.
Publicado: (2020)

Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes: Erratum
por: Llop, Esther, et al.
Publicado: (2018)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
por: James, Nicholas D., et al.
Publicado: (2022)

Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate
por: Takahara, Kiyoshi, et al.
Publicado: (2021)

Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study
por: Kobayashi, K, et al.
Publicado: (2020)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Erratum: Figurate Paraneoplastic Urticaria and Prostate Cancer
Publicado: (2012)

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study
por: Bryce, Jane, et al.
Publicado: (2012)

Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
por: Ni, Yu-Chao, et al.
Publicado: (2021)

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study
por: Fukasawa, Satoshi, et al.
Publicado: (2018)

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study
por: Suzuki, Hiroyoshi, et al.
Publicado: (2020)

Smartphone gaming and frequent use pattern associated with smartphone addiction: Erratum
Publicado: (2016)

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
por: Tehfe, Mustapha, et al.
Publicado: (2016)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Erratum to survival outcomes in prostate cancer patients with a prior cancer
Publicado: (2021)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

ERRATUM: Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor
por: Cho, Jang Ho, et al.
Publicado: (2018)

Erratum to Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fqif0hce6gfs75428ipte2fvjv